
News|Videos|March 7, 2025
The ARANOTE Phase 3 Trial of Darolutamide Plus Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer: Efficacy and Safety by Disease Volume
Author(s)Fred Saad, MD, FRCS
Dr. Fred Saad presents a post-hoc analysis of the Phase 3 ARANOTE trial, demonstrating that darolutamide plus androgen-deprivation therapy significantly improves radiographic progression-free survival and delays metastatic castration-resistant prostate cancer in patients with metastatic hormone-sensitive prostate cancer, with consistent efficacy across disease volume subgroups and a favorable safety profile.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
Nuvisertib Yields Strong Safety, Promising Efficacy in R/R Myelofibrosis
5



































